Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02093962 · ClinicalTrials.gov registry record · Phase 2
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
A Phase 2 study, sponsored by ImmunoGenesis.
- Terminated
- Registry status
- Phase 2
- Development phase
- 265
- Enrollment target
NCT02093962 is a Phase 2 study that was terminated before completion, run by ImmunoGenesis. The registered enrollment target is 265 participants.
The verdict
NCT02093962, a Phase 2 study, was terminated before completion, sponsored by ImmunoGenesis.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 265 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether TH-302 in combination with pemetrexed is safe and effective in the treatment of non-squamous non-small cell lung cancer.
Interventions
- DRUG TH-302 combination with pemetrexed
- DRUG Matched placebo in combination with pemetrexed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 265 participants |
| Start Date | 2014-06 |
| Est. Completion | 2016-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02093962
The ClinicalTrials.gov registry entry for NCT02093962 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 265 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunoGenesis, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TH-302 combination with pemetrexed is the first listed.
NCT02093962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02093962 about?
NCT02093962 is a clinical study titled "Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer". The purpose of this study is to determine whether TH-302 in combination with pemetrexed is safe and effective in the treatment of non-squamous non-small cell lung cancer.
What is the current status of trial NCT02093962?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 265 participants. The study started on 2014-06. Estimated completion is 2016-05.
What interventions are being tested in trial NCT02093962?
The interventions under investigation include: TH-302 combination with pemetrexed (DRUG), Matched placebo in combination with pemetrexed (DRUG).
Who is sponsoring clinical trial NCT02093962?
This trial is sponsored by ImmunoGenesis, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.